focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Share News (EVG)

  • There is currently no data for EVG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Northcoders launches bootcamp; Schroder invests

Thu, 04th Apr 2024 17:24

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Artemis Resources Ltd - gold, copper and lithium-focused exploration company with projects in Western Australia - Updates on Karratha gold project exploration programme in West Pilbara, Western Australia. Says Lulu Creek will be drill tested in the third quarter of 2024. Adds that programme of works is submitted and approved, with heritage clearance application underway.

----------

Develop North PLC - investor in residential and commercial property sector - Starts share buyback programme of up to GBP500,000. The programme is set to end on June 30 and could be terminated earlier.

----------

Evgen Pharma PLC - clinical stage drug development company developing sulforaphane-based medicines - Raises GBP51,670 via issuing 5.2 million retail offer shares at a price of 1 pence each. Applies to the London Stock Exchange for the admission of a total of 152.5 million new shares to trading on AIM, comprising of 79.4 million placing shares, 5.6 million subscription shares and 62.3 million initial consideration shares

----------

Genflow Biosciences PLC - London-based biotechnology company focused on longevity - Raises GBP715,000 via its broker Capital Plus Partners by placing 57.2 million shares. Chief Executive Officer Eric Leire invested GBP50,000 personally in the placing, the company says.

----------

Insig AI PLC - London-based data science and machine learning firm - Agrees to a GBP250,000 equity funding facility with Executive Chair Richard Bernstein, which will allow him to subscribe for up to around 1.3 million new shares at 20 pence per share until the end of August.

----------

Northcoders Group PLC - Manchester-based software coding training provider - Launches part-time business-to-costumer software development bootcamp that aims to make careers in tech more accessible. The virtual course will start in mid-July and has been created due to demand for alternative structures, Northcoders says. Chief Executive Officer Chris Hill says: "Not only is this in line with the group's strategy to address the nation's widening digital skills, but it embodies our commitment to inclusivity and flexibility, ensuring that anyone who is interested in the opportunity to work in the ever-growing UK technology market can pursue their ambitions, regardless of their schedule or background."

----------

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company - Raises GBP1.2 million via issuing 11.7 million fundraising shares at the placing price of 10p per share.

----------

Schroder BSC Social Impact Trust PLC - investment firm focused on positive social impact as well as long-term capital growth and income - Announces GBP5 million commitment to Savills IM Simplify Affordable Homes Ltd Partnership, which will lie within Schroder's High Impact Housing asset class allocation. "The UK continues to face a housing crisis with an acute lack of social and affordable housing and this fund will deliver homes for lower income households and people currently in need of social housing in areas in most need. The SAH management team have a strong track record, with over 30 years' expertise and deep sector knowledge with long standing housing association relationship. We believe they are well-placed to deliver high quality financial and impact returns through providing affordable housing at-scale," says Jeremy Rogers, chief investment officer of Big Society Capital, portfolio manager of Schroder BSC.

----------

By Tom Budszus, Alliance News slot editor

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
2 Aug 2023 10:09

AIM WINNERS & LOSERS: Deltex plummets on return to AIM; Blancco rises

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
13 Jul 2023 15:58

UK shareholder meetings calendar - next 7 days

Friday 14 July 
Templeton Emerging Markets Investment Trust PLCAGM
Monday 17 July 
All ThingsConsidered Group PLCAGM
Tower Resources PLCAGM
Tuesday 18 July 
Alkemy Capital Investments PLCAGM
Bloomsbury Publishing PLCAGM
CT Property Trust LtdGM re takeover by LondonMetric Property
e-Therapeutics PLCAGM
MobilityOne LtdEGM re Tete planned JV deadline extension
SmartSpace Software PLCAGM
Strategic Minerals PLCAGM
Wynnstay Properties PLCAGM
Wednesday 19 July 
Berkeley Energia LtdAGM
Caledonian Trust PLCAGM
DG Innovate PLCAGM
Experian PLCAGM
HICL Infrastructure PLCAGM
Mind Gym PLCAGM
Sportech PLCGM re share capital restructure
Triple Point Income VCT PLCAGM
Thursday 20 July 
ACG Acquisition Co LtdEGM re acquisition of the Atlantic Nickel
Big Yellow Group PLCAGM
CT UK High Income Trust PLCAGM
Evgen Pharma PLCAGM
FD Technologies PLCAGM
Fuller, Smith & Turner PLCAGM
GB Group PLCAGM
Halma PLCAGM
Intermediate Capital Group PLCAGM
International Distributions Services PLCAGM
Fidelity China Special Situations PLCAGM
Johnson Matthey PLCAGM
Kingspan Group PLCEGM re delisting
Pennon Group PLCAGM
Premier Foods PLCAGM
Premier Miton Group PLCAGM
Qinetiq Group PLCAGM
SSE PLCAGM
TR Property Investment Trust PLCAGM
VP PLCAGM
Weiss Korea Opportunity Fund LtdAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
27 Jun 2023 10:17

AIM WINNERS & LOSERS: Unbound shares drop as calls off sales process

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.

Read more
27 Jun 2023 10:01

Evgen Pharma's SFX-01 has positive effects for treating a rare cancer

(Alliance News) - Evgen Pharma PLC on Tuesday said its lead asset SFX-01 has radio-sensitising effects in vivo in a form of soft tissue sarcoma, as part of its research partnership with Sapienza University of Rome.

Read more
19 Jun 2023 10:05

Evgen collaborator receives grant from KWF Dutch Cancer Society

(Alliance News) - Evgen Pharma PLC on Monday said its collaborator at the Erasmus University Medical Center in Rotterdam has received notice of a grant from KWF Dutch Cancer Society.

Read more
7 Jun 2023 11:41

Evgen Pharma confident amid Stalicla deal; CFO Moulson to retire

(Alliance News) - Evgen Pharma PLC on Wednesday reported a widened annual loss and said its Chief Financial Officer Richard Moulson will retire in late July.

Read more
31 May 2023 15:46

UK earnings, trading statements calendar - next 7 days

Thursday 1 June 
Auto Trader Group PLCFull Year Results
Dr Martens PLCFull Year Results
Pennon Group PLCFull Year Results
Trinity Exploration & Production PLCFull Year Results
Friday 2 June 
TR Property Investment Trust PLCFull Year Results
Nostrum Oil & Gas PLCFull Year Results
Monday 5 June 
Celadon Pharmaceuticals PLCFull Year Results
Hercules Site Services PLCHalf Year Results
Itaconix PLCFull Year Results
Sirius Real Estate LtdFull Year Results
ValiRx PLCFull Year Results
Verici Dx PLCFull Year Results
Tuesday 6 June 
British American Tobacco PLCTrading Statement
Chemring Group PLCHalf Year Results
Ferguson PLCQ3 Results
Gooch & Housego PLCHalf Year Results
Jadestone Energy PLCFull Year Results
N Brown Group PLCFull Year Results
NewRiver REIT PLCFull Year Results
Oxford Metrics PLCHalf Year Results
Paragon Banking Group PLCHalf Year Results
Speedy Hire PLCFull Year Results
Warehouse REIT PLCFull Year Results
Wednesday 7 June 
discoverIE Group PLCFull Year Results
Evgen Pharma PLCFull Year Results
LXi REIT PLCFull Year Results
Ramsdens Holdings PLCHalf Year Results
Residential Secure Income PLCHalf Year Results
Vp PLCFull Year Results
  
Copyright 2023 Alliance News Ltd. All Rights Reserved.

Read more
22 Mar 2023 11:10

IN BRIEF: Evgen Pharma shares up as pharmacokinetic data announced

Evgen Pharma PLC - Cheshire, England-based clinical stage drug development company focusing on sulforaphane-based medicines - Presents top line pharmacokinetic data for its placebo-controlled, dose-escalating, randomised Phase I/Ib clinical trial. Says the study is aimed to provide further insight into the pharmacokinetic and pharmacodynamic characteristics of the new enteric coated tablet formulation of the company's lead asset SFX-01, as well as investigating how sulforaphane released from the tablet engages with targets of interest. Says SFX-01 shows no serious adverse effects and the study is on schedule for full reporting in the second quarter.

Read more
22 Mar 2023 10:30

AIM WINNERS & LOSERS: Pathfinder finds way forward in Mozambique

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
16 Mar 2023 16:35

Evgen notes evidence of radiosensitisation by SFX-01 in cancer cells

(Alliance News) - Evgen Pharma PLC said on Thursday it had found further evidence of radiosensitisation by SFX-01 in sarcoma cells.

Read more
13 Mar 2023 12:18

SUMMARY: London listings with exposure to Silicon Valley Bank

(Alliance News) - The following is a round-up of updates on exposure to Silicon Valley Bank by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jan 2023 10:40

Evgen Pharma completes dosing of clinical trial for SFX-01 tablet

(Alliance News) - Evgen Pharma PLC on Wednesday said it completed the dosing of all three cohorts of the phase 1/1b clinical trial of its SFX-01 tablet formulation.

Read more
8 Dec 2022 13:57

Evgen Pharma loss, operating expenses widen; SFX-01 study on schedule

(Alliance News) - Evgen Pharma PLC on Thursday said interim loss widened, but noted the healthy volunteer study of its SFX-01 formulation remains on schedule.

Read more
16 Nov 2022 16:11

Evgen Pharma starts clinical trial of new SFX-01 tablet

(Alliance News) - Evgen Pharma PLC said on Wednesday it had started a randomised, placebo-controlled clinical trial of its new SFX-01 tablet.

Read more
16 Nov 2022 14:05

Evgen Pharma doses first volunteers in SFX-01 trial

(Sharecast News) - Clinical-stage drug developer Evgen Pharma has dosed the first group of healthy volunteers in its placebo-controlled, dose-escalating, randomised phase 1 and 1b clinical trial, it announced on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.